Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		After market 23:19:06
9.32 USD -6.52% Intraday chart for Candel Therapeutics, Inc. 9.295 -0.27%
04-11 Sector Update: Health Care Stocks Decline Thursday Afternoon MT
04-11 Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug MT

Business Summary

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Number of employees: 42

Managers

Managers TitleAgeSince
Paul-Peter Tak CEO
 Chief Executive Officer 64 31/08/20
Estuardo Aguilar-Cordova FOU
 Founder 66 31/12/01
Charles Schoch DFI
 Director of Finance/CFO 39 -
Seshu Tyagarajan CTO
 Chief Tech/Sci/R&D Officer 57 01/03/22
Francesca Barone CTO
 Chief Tech/Sci/R&D Officer 47 31/10/20
William Nichols CTO
 Chief Tech/Sci/R&D Officer 55 11/09/22
Ileen B. Winick HRO
 Human Resources Officer - 31/12/20
Nathan Caffo PRN
 Corporate Officer/Principal 55 31/08/20
Susan Stewart LAW
 General Counsel 64 30/09/20

Members of the board

Members of the board TitleAgeSince
Joseph Papa BRD
 Director/Board Member 68 07/08/22
Edward Benz BRD
 Director/Board Member 78 31/08/17
Paul Manning CHM
 Chairman 68 31/10/18
Gary Nabel BRD
 Director/Board Member 70 07/08/22
Estuardo Aguilar-Cordova FOU
 Founder 66 31/12/01
Paul-Peter Tak CEO
 Chief Executive Officer 64 31/08/20
Renee Gaeta BRD
 Director/Board Member 42 07/08/22
Diem Nguyen BRD
 Director/Board Member 52 14/07/21
Christopher Martell BRD
 Director/Board Member 45 31/10/18
Nicoletta Loggia BRD
 Director/Board Member - 06/06/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,470,076 19,157,342 ( 65.01 %) 0 65.01 %

Shareholders

NameEquities%Valuation
Estuardo Aguilar-Cordova
10.91 %
3,153,815 10.91 % 5 M $
Laura Aguilar
10.49 %
3,032,700 10.49 % 5 M $
Paul Manning
9.949 %
2,877,158 9.949 % 5 M $
Northpond Ventures LLC
6.692 %
1,935,215 6.692 % 3 M $
Sands Capital Ventures LLC
2.807 %
811,737 2.807 % 1 M $
Vanguard Group, Inc. (Subfiler)
1.872 %
541,295 1.872 % 855 246 $
Christopher Martell
1.506 %
435,514 1.506 % 688 112 $
Banor Capital Ltd.
1.379 %
398,826 1.379 % 630 145 $
Fidelity Management & Research Co. LLC
1.032 %
298,384 1.032 % 471 447 $
Geode Capital Management LLC
0.4815 %
139,253 0.4815 % 220 020 $

Company contact information

Candel Therapeutics, Inc.

117 Kendrick Street Suite 450

02494, Needham

+

http://www.candeltx.com
address Candel Therapeutics, Inc.(CADL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.32 USD
Average target price
11 USD
Spread / Average Target
+18.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CANDEL THERAPEUTICS, INC. Stock Candel Therapeutics, Inc.
+534.01% 274M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CADL Stock
  4. Company Candel Therapeutics, Inc.